296 results about "Treatment outcome" patented technology

The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

Novel modalities are introduced to treat joint and cartilage ischemia and related pathologies to improve outcome in the treatment of arthropathies and spondylopathies. The invention includes compositions, materials or devices which will improve oxygen, substrate and nutrient delivery to joint tissues and modalities to decrease the degradation of joint tissues by inflammatory and other destructive processes.

Devices, systems, and methods for treating a heart of a patient may make use of structures which limit a size of a chamber of the heart, such as by deploying a tensile member to bring a wall of the heart toward (optionally into contact with) a septum of the heart. The implant may include an electrode or other structure for applying pacing signals to one or both ventricles of the heart, for defibrillating the heart, for sensing beating of the heart or the like. A wireless telemetry and control system may allowing the implant to treat congestive heart failure, monitor the results of the treatment, and apply appropriate electrical stimulation.

Methods for classifying and for evaluating the prognosis of a subject having breast cancer are provided. The methods include prediction of breast cancer subtype using a supervised algorithm trained to stratify subjects on the basis of breast cancer intrinsic subtype. The prediction model is based on the gene expression profile of the intrinsic genes listed in Table 1. This prediction model can be used to accurately predict the intrinsic subtype of a subject diagnosed with or suspected of having breast cancer. Further provided are compositions and methods for predicting outcome or response to therapy of a subject diagnosed with or suspected of having breast cancer. These methods are useful for guiding or determining treatment options for a subject afflicted with breast cancer. Methods of the invention further include means for evaluating gene expression profiles, including microarrays and quantitative polymerase chain reaction assays, as well as kits comprising reagents for practicing the methods of the invention.

A medical treatment planning system includes a computer including a processor and memory, data stored in the memory, said data including a priori of information relating to medical conditions, medical treatments and treatment results, and treatment planning logic stored in the memory and executable by the processor. The treatment planning logic includes logic that obtains pre-treatment patient data describing the patient's medical condition, logic that analyzes the pre-treatment patient data relative to the a priori of information and, based on the analysis, formulates a first treatment plan for treating the patient, and logic that outputs the first treatment plan for evaluation by medical personnel.

A method of computer aided treatment planning is performed by generating and manipulating a three dimensional (3D) image of a region which includes at least one anatomical structure for which treatment, such as surgery, biopsy, tissue component analysis, prosthesis implantation, radiation, chemotherapy and the like, is contemplated. A virtual intervention, which simulates at least a portion of the contemplated treatment, is performed in the 3D image. The user can then determine the effect of the intervention and interactively modify the intervention for improved treatment results. Preferably, a warning is automatically provided if the intervention poses a risk of detrimental effect. The user can navigate through the contemplated region in the 3D image and assess the results. The treatment plans can be saved for comparison and post treatment evaluation.

Novel systems and methods for performing treatment (e.g., coloration) of keratinous fibers are disclosed. The methods and systems utilize one or more of a dispensing device which is configured to provide customized composition for treating keratinous fibers (e.g., a coloring composition), optionally formed from tablets; an optical reader, for obtaining sufficient characteristics of the keratinous fibers to make a realistic prediction of the outcome of a treatment (e.g., coloring treatment); a computational units for predicting an outcome of a treatment, optionally being interfaced with the dispensing device and for selecting a customized treatment; and tablet formulations which are useful in preparing customized composition for treating keratinous fibers. Further disclosed are rapidly disintegrating tablets for use in the preparation of compositions for treating keratinous fibers.

Appropriate assessment of wound oxygenation is critical to establish a diagnosis, to monitor the effect of the treatment, to guide the therapeutic process, to identify the presence of infection, and to predict the treatment outcome. Embodied systems and methods represent an enabling technology for noninvasive and objective assessment of wound tissue oxygenation. In addition to wound healing, disclosed embodiments offer low cost and portable avenues for noninvasive assessment of multiple clinical parameters for the detection and intervention of various malignancies in multiple soft tissue systems.

Present invention relates to a novel pharmaceutical composition containing an active ingredient(s) which is retained in the stomach or upper part of gastrointestinal tract for controlled delivery of medicament for improved local treatment, and/or better absorption from upper parts of gastrointestinal tract for effective therapeutic results. Present invention also provides a method for preparation of the said dosage form preferably in the form of a bilayer tablet, in which one layer constitutes for spatial control and the other being for temporal control.

The invention provides compositions and methods for determining the increased risk for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprise determining the type of genomic polymorphism present in a predetermined region of the gene of interest isolated from the subject or patient. Also provided are nucleic acid probes and kits for determining a patient's cancer risk and treatment response.

Physiological imaging-defined subvolumes of tissues/disease are identified to yield spatially-defined prognostic and/or predictive indicators and/or focal therapy targets within such tissues, in particular tumors, for evaluation over time, for example, prior to and after a therapy treatment. Medical image data is analyzed to delineate subvolumes of tissue based upon multiple physiological, metabolic, and biological imaging properties, where those subvolumes are extracted and analyzed in a probabilistic manner to associate with one or more abnormal or disease phenotype conditions.

This invention relates to a composition and method for treating diseases and disorders of the prostate such as prostatitis, benign prostatic hypertrophy, and prostate carcinoma. The prostate is treated by intraprostatic injection of a biodegradable sustained release formulation. By injecting the treatment substance directly into the prostate, improved treatment results are obtained with a much lower treatment substance dosage. Additionally, by incorporating the treatment substance into a biodegradable sustained release formulation, the need for frequent repetition of injections is eliminated.

The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.

Systems and methods for displaying a predicted outcome of a lung volume reduction procedure for a patient including a user interface, a processor, and programing operable on the processor for displaying a predicted outcome of the bronchoscopic lung volume reduction procedure on the user interface, wherein displaying the predicted outcome of the lung volume reduction procedure includes receiving patient data comprising volumetric images of the patient, analyzing the volumetric images to identify one or more features correlated to treatment outcome prediction, predicting an outcome for a treatment modality or treatment device using the one or more identified features, and displaying the predicted outcome on the user interface.

The invention provides compositions and methods for determining the increased risks for recurrence of certain cancers and the likelihood of successful treatment with one or both of chemotherapy and radiation therapy. The methods comprising determining the type of genomic polymorphism present in a predetermined region of the gene of interest isolated from the subject or patient. Also provided are nucleic acid probes and kits for determining a patient's cancer risk and treatment response.

Methods of using zonisamide as an adjunctive therapy for partial seizures are disclosed. In particular, the methods enhance the safety of patients taking pharmaceutical formulations of zonisamide by providing information that increases the awareness of pancreatitis as a possible side effect; wherein the patients and/or prescribing physicians and other medical care providers are advised to monitor for pancreatitis and employ methods that will improve the therapeutic outcome in the few patients who experience pancreatitis associated with zonisamide therapy.

Methods of using zonisamide as an adjunctive therapy for partial seizures are disclosed. In particular, the methods enhance the safety of patients taking pharmaceutical formulations of zonisamide by providing information that increases the awareness of pancreatitis as a possible side effect; wherein the patients and/or prescribing physicians and other medical care providers are advised to monitor for pancreatitis and employ methods that will improve the therapeutic outcome in the few patients who experience pancreatitis associated with zonisamide therapy.

Herein described is an apparatus and method for stabilizing, restraining and positioning a patient during human medical or veterinary procedures, for example, diagnostic imaging procedures, such as Magnetic Resonance Imaging (MRI) and Computerized Tomography scanning procedures, or therapeutic procedures, such as stereotactic radiosurgery. The restraining apparatus of the present invention, comprised of a castable sleeve and optional expandable element, sufficiently immobilizes the patient so as to eliminate motion artifact and motion degradation, to thereby provide improved imaging and/or therapy results.

A system for imaging high speed moving objects, for example, using a scanning beam and beam delivery optics with fast signal processing. It can allow for vocal fold imaging at up to or exceeding approximately 1000 frames per second with grayscale resolution as high as about 100 micrometers or higher and up to about a 12.4 mm square or larger viewing area. The invention can provide imaging of vocal fold vibration that correlates completely with a synchronously-acquired acoustic voice signal. This can enable physicians, voice therapists and research scientists to understand the consequences of abnormal laryngeal dynamics, rather than being limited to simply observing the dynamics. Further, the application of laser technology will allow for accurate measurements of dimension. This can objectify examination findings and treatment outcomes measurement, helping to overcome the serious limitations of current perceptual-based judgments.